Compare FLWS & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLWS | HELP |
|---|---|---|
| Founded | 1976 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.5M | 279.9M |
| IPO Year | 1999 | N/A |
| Metric | FLWS | HELP |
|---|---|---|
| Price | $4.55 | $4.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | ★ 787.9K | 715.8K |
| Earning Date | 05-07-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,151,921,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $4.15 |
| 52 Week High | $8.44 | $8.55 |
| Indicator | FLWS | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 42.11 |
| Support Level | $3.07 | $4.52 |
| Resistance Level | $5.08 | $6.26 |
| Average True Range (ATR) | 0.32 | 0.25 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 75.23 | 31.25 |
1-800-Flowers.com Inc is a provider of gifts designed to help customers express, connect, and celebrate. The company's e-commerce business platform features all brands, including 1-800-Flowers.com, 1-800-Baskets.com, Cheryl's Cookies, Harry and David, PersonalizationMall.com, Shari's Berries, FruitBouquets.com, Moose Munch, The Popcorn Factory, Wolferman's Bakery, Stock Yards, and Simply Chocolate. The company's business segments are; Consumer Floral and Gifts, BloomNet, and Gourmet Foods & Gift Baskets. The maximum revenue for the company is generated from its Gourmet Foods & Gift Baskets segment.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.